King Confident Of Embeda Okay In 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite a recent, significant downsizing, King is ready to launch the abuse-resistant drug.
You may also be interested in...
Generic Skelaxin Moves Closer As King Loses Patent Case; Last Hurdle Is FDA
Following a win in its patent case against King, Sandoz appears to have only one hurdle remaining before it can launch a generic of Skelaxin (metaxalone) - FDA approval of its ANDA
Third Time’s Not The Charm For King’s Pursuit of Alpharma
As King Pharmaceuticals tries to move past the hit from the entry of generic competition for Altace and overall lackluster second quarter sales figures, the firm has embarked on a plan to become a powerhouse specialty therapeutic pain company, and a central piece of that plan is the acquisition of Alpharma. But Alpharma will have none of it
Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?